A method of determining if a subject has an increased risk of suffering from memory impairment relating to amnestic mild cognitive impairment or Alzheimer's Disease, the method comprising a) analyzing at least one sample from the subject to determine the subject's plasma concentration of each component in a metabolite profile, wherein the metabolite profile comprises the components propionylcarnitine, phosphatidylcholine with the diacyl residue sum C32:0 (PC aa C32:0), phosphatidylcholine with the diacyl residue sum C40:5 (PC aa C40:5), hydroxyisovaleryl carnitine (C5-OH (C3-DC-M)), phosphatidylcholine with the acyl/alkyl residue sum C34:0 (PC ae C34:0), hydroxyoctadecenoylcarnitine (C18:1-OH), phosphatidylcholine with the diacyl residue sum C34:4 (PC aa C34:4), phosphatidylcholine with the diacyl residue sum C38:4 (PC aa C38:4), isovalerylcarnitine, phosphatidylcholine with the diacyl residue sum C38:3 (PC aa C38:3), lysophosphatidylcholine with the acyl residue sum C18:0 (lysoPC a C18:0), decadienoylcarnitine (C10:2), dodecenoylcarnitine (C12:1), hexadecadienoylcarnitine (C16:2), decenoylcarnitine (C10:1), asparagine (Asn) and asymmetric dimethylarginine (ADMA) and b) comparing the subject's plasma concentration of each component in the metabolite profile with the plasma concentration of each component obtained from subjects determined to define a normal metabolite profile, wherein it is indicated that the subject has an increased risk of suffering from future memory impairment if (i) the subject's plasma concentration of the components C3, PC aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH), PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA are lower as compared to the plasma concentration of C3, PC aa C32:0, PC aa C40:5, C5-OH, PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA, respectively, obtained from subjects determined to define a normal metabolite profile, and (ii) the subject's plasma concentration of the components C12:1, C16:2, and C10:1 are higher as compared to the plasma concentration of C12:1, C16:2, and C10:1, respectively, obtained from subjects determined to define a normal metabolite profile. a) analyzing at least one sample from the subject to determine the subject's plasma concentration of each component in a metabolite profile, wherein the metabolite profile comprises the components propionylcarnitine, phosphatidylcholine with the diacyl residue sum C32:0 (PC aa C32:0), phosphatidylcholine with the diacyl residue sum C40:5 (PC aa C40:5), hydroxyisovaleryl carnitine (C5-OH (C3-DC-M)), phosphatidylcholine with the acyl/alkyl residue sum C34:0 (PC ae C34:0), hydroxyoctadecenoylcarnitine (C18:1-OH), phosphatidylcholine with the diacyl residue sum C34:4 (PC aa C34:4), phosphatidylcholine with the diacyl residue sum C38:4 (PC aa C38:4), isovalerylcarnitine, phosphatidylcholine with the diacyl residue sum C38:3 (PC aa C38:3), lysophosphatidylcholine with the acyl residue sum C18:0 (lysoPC a C18:0), decadienoylcarnitine (C10:2), dodecenoylcarnitine (C12:1), hexadecadienoylcarnitine (C16:2), decenoylcarnitine (C10:1), asparagine (Asn) and asymmetric dimethylarginine (ADMA) and b) comparing the subject's plasma concentration of each component in the metabolite profile with the plasma concentration of each component obtained from subjects determined to define a normal metabolite profile, (i) the subject's plasma concentration of the components C3, PC aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH), PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA are lower as compared to the plasma concentration of C3, PC aa C32:0, PC aa C40:5, C5-OH, PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA, respectively, obtained from subjects determined to define a normal metabolite profile, and (ii) the subject's plasma concentration of the components C12:1, C16:2, and C10:1 are higher as compared to the plasma concentration of C12:1, C16:2, and C10:1, respectively, obtained from subjects determined to define a normal metabolite profile.